Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial

Vaccine

Volumn 33, Issue 10, 2015, Pages 1284-1290

  Lehtinen, Matti ^a   Apter, Dan ^b   Baussano, Iacopo ^c   Eriksson, Tiina ^a   Natunen, Kari ^a   Paavonen, Jorma ^e   Vänskä, Simopekka ^d   Bi, Dan ^f   David, Marie Pierre ^f   Datta, Sanjoy ^f   Struyf, Frank ^f   Jenkins, David ^g   Pukkala, Eero ^a   Garnett, Geoff ^h   Dubin, Gary ⁱ  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b Family Federation of Finland ^*  (Finland)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f GSK   (Belgium)

^g DDL DIAGNOSTIC LABORATORY   (Netherlands)

^h BILL AND MELINDA GATES FOUNDATION   (United States)

ⁱ GLAXOSMITHKLINE   (United States)

Author keywords

Herd effect; HPV vaccines; Human papillomavirus

Indexed keywords

HEPATITIS B VACCINE; WART VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; VIRUS LIKE PARTICLE VACCINE;

ADOLESCENT; ADOLESCENT SEXUAL BEHAVIOR; ADULT; ALCOHOL CONSUMPTION; ARTICLE; CHILD; DRUG EFFICACY; EJACULATION; FEMALE; GENITAL TRACT CANCER; HERD IMMUNITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LIFESTYLE; MALE; MENARCHE; NONHUMAN; OROPHARYNX CANCER; PRECANCER; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHOOL CHILD; SEROPREVALENCE; SMOKING HABIT; VACCINATION; CLINICAL TRIAL; CONTROLLED STUDY; HEPATITIS B VIRUS; IMMUNOLOGY; MASS IMMUNIZATION; PAPILLOMAVIRUS INFECTIONS; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; STATISTICS AND NUMERICAL DATA; UTERINE CERVICAL NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; CHILD; FEMALE; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNITY, HERD; MALE; MASS VACCINATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEROEPIDEMIOLOGIC STUDIES; SEXUAL BEHAVIOR; SURVEYS AND QUESTIONNAIRES; UTERINE CERVICAL NEOPLASMS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84922583168     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.12.019     Document Type: Article

References (33)

1. EMA European public assessment report 2006, http://www.ema.europa.eu/PDFs/EPAR/gardasil/.
2. EUROPA European public assessment report 2007, http://www.europa.eu/PDFs/EPAR/cervarix/.
3. Markowitz L., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R. Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices. MMWR 2007, 56:1-24.
4. FDA FDA approves new vaccine for prevention of cervical cancer 2009, http://www.fda.gov/.
5. Lehtinen M., Dillner J. Clinical HPV vaccine trials and beyond. Nat Rev Clin Oncol 2013, 10:400-410.
6. Lehtinen M., Herrero R., Mayaud P., Barnabas R., Dillner J., Paavonen J., et al. Studies to assess long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 2006, 24S:233-241.
7. Rana M., Huhtala H., Apter D., Eriksson T., Luostarinen T., Natunen K., et al. Understanding of long-term protection of human papillomavirus vaccination against cervical carcinoma. Int J Cancer 2013, 132:2833-2838.
8. Petaja T., Keränen H., Karppa T., Kawa A., Lantela S., Siitari-Mattila M., et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04 adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009, 44:33-41.
9. Palefsky J.M., Giuliano A.R., Goldstone S., Moreira E.D., Aranda C., Jessen H., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011, 365:1576-1585.
10. Stanley M. Vaccinate boys too. Nature 2012, 488:S10.
11. http://www.hpvvaccine.org.au/.
12. European Cervical Cancer Association HPV vaccination across Europe 2011, http://www.ecca.info/en/ecca-publications.html.
13. Markowitz L.E., Tsu V., Deeks S.L., Cubie H, Wang S.A., Vicari A.S., et al. Human papillomavirus vaccine introduction - the first five years. Vaccine 2012, 30:F139-F148.
14. Brotherton J., Fridman J.M., May C.L., Chappell G., Saville A.M., Gertig D.M. Early effect of HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377:2085-2092.
15. Taylor R., Hariri S., Sternberg M., Dunne E.F., Markowitz L. Human papillomavirus vaccine coverage in the United States: National Health and Nutrition Examination Survey, 2007-2008. Prev Med 2011, 52:398-400.
16. Dorell C.G., Stokley S., Yankey D., Markowitz L.E. Compliance with recommended dosing intervals for HPV vaccination among females, 13-17 years, National Immunization Survey-Teen, 2008-2009. Vaccine 2011, 30:503-505.
17. Brabin L., Roberts S.A., Stretch R., Baxter D., Chambers G., Kitchener H., et al. Uptake of the first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 2008, 336:1056-1058.
18. Gertig D.M., Brotherton J.M., Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011, 8:171-178.
19. Kavanagh K., Pollock K.G., Potts A., Love J., Cuschieri K., Cubie H., et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014, 110:2804-2811.
20. Malmqvist E., Natunen K., Lehtinen M., Helgesson G. Just implemention of human papillomavirus vaccination. J Med Ethics 2012, 38:247-249.
21. Vänskä S., Auranen K., Leino T., Salo H., Nieminen P., Kilpi T., et al. Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach. PLoS ONE 2013, 8:e72088.
22. Baussano I., Elfström K.M., Lazzarato F., Gillio-Tos A., De Marco L., Carozzi F., et al. Type-specific human papillomavirus biological features: validated model-based estimates. PLoS ONE 2013, 8:e81171.
23. Lehtinen M., Kaasila M., Pasanen K., Patama T., Palmroth J., Laukkanen P., et al. Seroprevalence ATLAS of HPV infections in Finland. Int J Cancer 2006, 120:2612-2619.
24. Kaasila M., Koskela P., Kirnbauer R., Pukkala E., Surcel H.-M., Lehtinen M. Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women. Int J Cancer 2009, 125:2166-2172.
25. Lehtinen M., Paavonen J. Effectiveness of preventive HPV vaccination. Int J STD & AIDS 2003, 14:787-792.
26. Lehtinen M., French K., Dillner J., Paavonen J., Garnett G. Sound implementation of HPV vaccination. Future Med 2008, 5:289-294.
27. HILMO Sosiaalihuollon-ja terveydenhuollon hoitoilmoitus. Ohjeita ja luokituksia. Stakes 2006, 2.
28. Pukkala E., Andersen A., Berglund G., Gislefoss R., Gudnason V., Hallmans G., et al. Nordic biological specimen banks as basis for studies of cancer causes and control - 25 million person-years and 100,000 prospective cancers. Acta Oncol 2007, 46:286-307.
29. Barnabas R., Laukkanen P., Koskela P., Kontula O., Lehtinen M., Garnett G.P. The epidemiology of HPV16 and cervical cancer in Finland and the potential of vaccination. PLoS Med 2006, 3:e138.
30. Castro F., Haimila K., Pasanen K., Kaasila M., Patama T., Partanen J., et al. Geographic distribution of cervical cancer associated HLA antigens and cervical cancer incidence in fertile-aged Finnish women. Int J STD & AIDS 2007, 18:672-679.
31. Ramqvist T., Dalianis T. Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis 2010, 11:1671-1677.
32. Azvolinsky A. Concerned about HPV-related cancer rise, researchers advocate boosting HPV vaccination rates. J Natl Cancer Inst 2013, 105:1335-1336.
33. Wheeler C.M., Castellsague X., Garland S., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.